Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FLI1 | Q01543 | 1/20 | 0.43 |
| ▸ | EWSR1 | Q01844 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11686001 | 0.85 | SMN1; SMN2 (0.62) | HPGDKDM4ESMN1; SMN2KMT2ACYP1A2 | |
| SCHEMBL5717808 | 0.85 | KMT2A (0.63) | HAO1HPGDSMN1; SMN2PLK1MMP2 | |
| SCHEMBL7575160 | 0.85 | NR4A2 (0.59) | HAO1HPGDKDM4ESMN1; SMN2PLK1 | |
| SCHEMBL5190530 | 0.83 | HAO1 (0.50) | HAO1SMN1; SMN2PLK1MMP2MMP9 | |
| SCHEMBL4707187 | 0.82 | HAO1 (0.62) | HAO1HPGDKDM4ESMN1; SMN2PLK1 | |
| SCHEMBL7196791 | 0.82 | L3MBTL1 (0.55) | HAO1PLK1MMP2MMP9MMP8 | |
| SCHEMBL6755453 | 0.82 | HSD17B3 (0.62) | HAO1HPGDSMN1; SMN2PLK1MMP2 | |
| SCHEMBL459999 | 0.81 | ALDH1A1 (0.53) | HAO1HPGDSMN1; SMN2PLK1MMP2 | |
| SCHEMBL18193726 | 0.81 | HAO1 (0.51) | HAO1HPGDPLK1MMP2MMP9 | |
| SCHEMBL7862887 | 0.80 | SMN1; SMN2 (0.66) | HAO1HPGDSMN1; SMN2PLK1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201611-B2 | Composition comprising high purity pyrrole derivative and method for preparation thereof | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-01-21 | — | — | US | disclosed |
| US-20220023262-A1 | COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-01-27 | — | — | US | disclosed |
| US-20220023262-A1 | COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-01-27 | — | — | US | disclosed |
| EP-3004053-B1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| US-10435363-B2 | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | CADILA HEALTHCARE LIMITED (IN) | 2019-10-08 | — | — | US | disclosed |
| US-20170144968-A1 | PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2017-05-25 | — | — | US | disclosed |
| US-20170144968-A1 | PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2017-05-25 | — | — | US | disclosed |
| EP-3156398-A1 | AGONISTS OF THE CHEMOKINE RECEPTOR CXCR3 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2017-04-19 | — | — | EP | disclosed |
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2016-07-07 | — | — | US | disclosed |
| US-7166618-B2 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1246621-A4 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1369415-A1 | Substituted pyrrolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030220228-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NICOX S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| US-6649629-B2 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NITROMED, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-0946507-B1 | SUBSTITUTED PYRROLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-1246621-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NICOX S.A. (FR) | 2001-11-15 | — | — | US | disclosed |
| WO-2001045703-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-5935990-A | PYRROLYL DERIVATIVES HAVING AT POSITION 1 OR 5 A PHENYL SUBSTITUTED WITH METHYLSULFONYL OR AMINOSULFONYL; INHIBIT CYCLOOXYGENASE-2 FOR USE TREATMENT OF INFLAMMATION, AS AN ANALGESIC, OR AS AN ANTIPYRETIC | G.D. SEARLE & CO. (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | HPD, HMGCR, CYP51A1 | HAO1 799/4885HPGD 654/4885KDM4E 373/4885 |
| US-20170144968-A1 | PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CYP51A1, LIPA, DHCR7 | HAO1 1312/4885HPGD 356/4885KDM4E 560/4885 |
| US-20030220228-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | PTGS2, PTGS1, PTGES2 | HAO1 122/4885HPGD 14/4885KDM4E 2379/4885 |
| US-12201611-B2 | Composition comprising high purity pyrrole derivative and method for preparation thereof | DHPS, OGFOD1, OGDH | HAO1 505/4885HPGD 61/4885KDM4E 176/4885 |
| US-10435363-B2 | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | CYP51A1, LIPA, DHCR7 | HAO1 1312/4885HPGD 356/4885KDM4E 560/4885 |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | PTGS1, PTGS2, PTGES | HAO1 147/4885HPGD 14/4885KDM4E 1418/4885 |
| US-20220023262-A1 | COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | DHPS, OGFOD1, OGDH | HAO1 505/4885HPGD 61/4885KDM4E 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.